Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218426 · ClinicalTrials.gov registry record · Phase 2
Addiction Treatment in Russia: Oral vs. Naltrexone Implant
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 306
- Enrollment target
NCT00218426: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00218426 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 306 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218426, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 306 participants
- Enrollment target
Study Summary
Heroin addiction is a growing problem in Russia; individuals who enter heroin addiction treatment often relapse. Therefore, effective heroin addiction treatments are necessary to prevent relapse. The purpose of this study is to compare oral naltrexone with a naltrexone implant that provides opioid blockade for two months in preventing relapse to heroin addiction in St. Petersburg, Russia.
Interventions
- DRUG oral naltrexone
- DRUG naltrexone implant
- DRUG oral placebo naltrexone
- DRUG placebo implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218426
The ClinicalTrials.gov registry entry for NCT00218426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which oral naltrexone is the first listed.
NCT00218426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218426 about?
NCT00218426 is a clinical study titled "Addiction Treatment in Russia: Oral vs. Naltrexone Implant". Heroin addiction is a growing problem in Russia; individuals who enter heroin addiction treatment often relapse. Therefore, effective heroin addiction treatments are necessary to prevent relapse. The purpose of this study is to compare oral naltrexone with a naltrexone implant that provides opioid b...
What is the current status of trial NCT00218426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 306 participants. The study started on 2006-07. Estimated completion is 2010-11-04.
What interventions are being tested in trial NCT00218426?
The interventions under investigation include: oral naltrexone (DRUG), naltrexone implant (DRUG), oral placebo naltrexone (DRUG), placebo implant (DRUG).
Who is sponsoring clinical trial NCT00218426?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.